Literature DB >> 6196822

Advantages of dextran 70 over Ringer acetate solution in shock treatment and in prevention of adult respiratory distress syndrome. A randomized study in man after traumatic-haemorrhagic shock.

J Modig.   

Abstract

Twenty-three patients aged 20-58 years in a serious state of shock and suffering from major pelvic and femoral fractures sustained in traffic accidents were studied. As initial fluid management, either dextran 70 (1000-1500 ml) together with Ringer's acetate solution (2000-3000 ml), or Ringer's acetate alone (5000-8000 ml), was administered on a random basis. Thus, 12 patients received dextran and 11 patients crystalloid treatment to counteract shock. Both groups were given whole blood. The resuscitation time--i.e. the interval from the start of fluid therapy until a stable circulatory condition was achieved--was significantly shorter (P less than 0.001) in the dextran group (108 +/- 18 min; mean +/- S.D.) than in the Ringer group (170 +/- 43 min). During the post-resuscitative observation period of 6 days the dextran patients were given 500 ml of dextran daily, while the Ringer group did not receive any colloidal solution. To maintain a stable circulation and a urinary output above 50 ml/h the Ringer patients required significantly more (P less than 0.001) crystalloid solution (910 +/- 300 ml) daily than the dextran patients (460 +/- 400 ml). The frequency of adult respiratory distress syndrome (ARDS) was significantly lower (P less than 0.05) in the dextran group (0 of 12) than in the Ringer group (4 of 11). Thus, in the initial treatment of traumatic-haemorrhagic shock and in the post-resuscitative period dextran 70 would seem of advantage over Ringer's acetate both in shortening the shock period and in reducing the frequency of adult respiratory distress syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196822     DOI: 10.1016/0300-9572(83)90024-2

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  11 in total

Review 1.  Intravenous Fluid Therapy in Traumatic Brain Injury and Decompressive Craniectomy.

Authors:  Hernando Raphael Alvis-Miranda; Sandra Milena Castellar-Leones; Luis Rafael Moscote-Salazar
Journal:  Bull Emerg Trauma       Date:  2014-01

2.  A new approach to physiology, monitoring, and therapy of shock states.

Authors:  W C Shoemaker
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

3.  Fluid therapy in shock.

Authors:  G Arturson; L Thorén
Journal:  World J Surg       Date:  1983-09       Impact factor: 3.352

Review 4.  Colloid solutions: a clinical update.

Authors:  Tomi T Niemi; Ryo Miyashita; Michiaki Yamakage
Journal:  J Anesth       Date:  2010-10-17       Impact factor: 2.078

Review 5.  Fluid resuscitation in diabetic emergencies--a reappraisal.

Authors:  K Hillman
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

6.  Fluid therapy in neurotrauma: basic and clinical concepts.

Authors:  Hernando Raphael Alvis-Miranda; Andres M Rubiano; Juan C Puyana; Gabriel Alcala-Cerra; Luis Rafael Moscote-Salazar
Journal:  Rev Health Care       Date:  2014

7.  Relation of oxygen transport patterns to the pathophysiology and therapy of shock states.

Authors:  W C Shoemaker
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

Review 8.  Measurement of tissue perfusion by oxygen transport patterns in experimental shock and in high-risk surgical patients.

Authors:  W C Shoemaker; P L Appel; H B Kram
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 9.  The appropriate role of colloids in managing fluid imbalance: a critical review of recent meta-analytic findings.

Authors:  A R Webb
Journal:  Crit Care       Date:  2000-10-13       Impact factor: 9.097

10.  Colloids versus crystalloids for fluid resuscitation in critically ill people.

Authors:  Sharon R Lewis; Michael W Pritchard; David Jw Evans; Andrew R Butler; Phil Alderson; Andrew F Smith; Ian Roberts
Journal:  Cochrane Database Syst Rev       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.